Menu
Your Cart

Rifaxa 200Mg Tablets

Rifaxa 200Mg Tablets - (005577) - www.mycare.lk
Rifaxa 200Mg Tablets
Rs.85.71
Price per unit
  • Stock: 20
  • Model: Rifaxa 200Mg Tablets
  • SKU: 005577
  • Pack size: 10
  • Generic name: Rifaximin
Add to Cart

Description RIFAXA tablets contain rifaximin, a non-aminoglycoside semisynthetic, nonsystemic antibiotic derived from rifamycin SV. Rifaximin is a structural analog of rifampin. The chemical name for rifaximin is (2s, 16Z, 18E, 20S, 21S, 22R, 23R, 24R, 25S, 26S, 27S, 28E), 23, 25-pentahydroxy-27-methoxy 2, 4, 11, 16, 20, 22, 24, 26-octamethyl-2, 7- (epoxy pentadeca- [1, 11, 13] trienimino) benzofuro [4, 5-e] pyrido [1, 2-a]- benzimidazole-1, 15 (2H)-Dione, 25-acetate. The empirical formula is C43 H51 N3 O11 and its molecular weight is 785.9. 

Indications & Usage: Travelers' Diarrhea: RIFAXA 200 mg is indicated for the treatment of patients (2 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. Limitations of use: RIFAXA should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Hepatic Encephalopathy: RIFAXA 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 2 18 years of age. In the trials of RIFAXA for HE, 91% of the patients were using lactulose concomitantly. Differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed. RIFAXA has not been studied in patients with MELD (Model for End-Stage Liver Disease) scores > 25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. 

Contraindications: Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation. 

Warning/Precautions: Concerns related to adverse effects: Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated Diarrhea (CDAD) and pseudomembranous colitis; CDAD has -anted months post antibiotic treatment. Disease-related concerns: Diarrhea: Appropriate use: Efficacy has not been established for the treatment of diarrhea due to pathogens other than E. coli, including C. jejuni, Shigella and Salmonella; consider alternative therapy if symptoms persist or worsen after 2448 hours of treatment; avoid use in diarrhea with fever or blood in the stool. Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score >25; use caution in patients with severe hepatic impairment (Child Pugh class C). Other warnings/ precautions: Appropriate use: Not for treatment of systemic infections; <1% is absorbed orally. 

Drug Interactions: BCG: Antibiotics may diminish the therapeutic effect of BCG. Risk X: Avoid combination. 

Pregnancy risk factor C: PREGNANCY IMPLICATIONS: Due to the limited oral absorption of rifaximin (<0.4%), exposure to the fetus is expected to be extremely low. 

Lactation: Excretion in breast milk unknown/not recommended. 


Manufactured by: FEROZSONS LABORATORIES LIMITED 

Write a review

Note: HTML is not translated!
Bad Good